According to the latest report by IMARC Group, titled "Human Microbiome Market Report by Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs, Medical Food, and Others), Application (Therapeutics, Diagnostics), Disease Type (Obesity, Diabetes, Autoimmune Disorders, Cancer, Gastrointestinal Disorders, Central Nervous System Disorders, and Others), and Region 2025-2033," the global human microbiome market size reached USD 958.6 Million in 2024. The human microbiome refers to the collection of microbial genomes that contribute to the metagenome of a human. It comprises a diverse array of microorganisms, such as archaea, bacteria, fungi, and nonliving viruses and protozoans. It is a genetic substance that is majorly present in human guts, particularly in the large intestine. It consists of numerous bacteria that aid in food digestion, regulating the immune system and producing vitamins, including B vitamins B12, riboflavin and thiamine, and Vitamin K, which are required for blood coagulation.
Global Human Microbiome Market Trends:
The global market is primarily driven by the rising prevalence of microbial dysbiosis among the masses. Coupled with this, the growing geriatric population, which is prone to chronic ailments, is impacting the market growth favorably. Along with this, extensive research and development (R&D) activities conducted by key players in the field of life science and biotechnology are creating a positive market outlook. In line with this, the increasing focus on immunity development due to the sudden outbreak of the coronavirus disease (COVID-19) is providing an impetus to the market. With the rapid advancements in analytical techniques and sequencing methods that aid in enhancing the ability to gain insights into the human microbiome, this is acting as another major growth-inducing factor. This is due to continuous technological advancements and the growing investments by public and private agencies in upgrading the overall biotechnology infrastructure. Other factors, including rapid digitization and the emerging pharmaceutical industry, are also positively influencing the market. On account of the aforementioned factors, the market is anticipated to reach a value of USD 4,038.6 Million by 2033, exhibiting a CAGR of 16.46% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Application, Disease Type, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | 4D pharma plc, Atlas Biomed Group Limited, BIOHM, BiomX, Bione, DayTwo Inc., ENTEROME, Ferring B.V., Finch Therapeutics, Second Genome Inc., SynBioBeta LLC, Synthetic Biologics Inc., Vedanta Biosciences Inc. and Viome Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800